Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Physicians who Perform Procedures using MammoSite

Articles with lock require a subscription to GLG News | Request a free trial
September 25, 2008
Tomotherapy, Protons, Short Course Breast RT - ASTRO 2008
Analysis of: Hospitals Look to Nuclear Tool to Fight Cancer | www.nytimes.com
Author: GLG Expert Contributor
Tomotherapy may do well after all with newer bells and whistles introduced at ASTRO 2008. Protons are likely to die leaving investors with a huge bill and dwindling ROI. Short course breast radiotherapy is not worth the risk.
May 27, 2008
You get what you pay for
Analysis of: Look to England's example for ways to solve America's health-care problem | www.sltrib.com
Author: GLG Expert Contributor
A single payer, national system does work, but may not necessarily be in the best interest of all parties.   Yes this type of system is 'free' to the users, but is funded through higher taxes than paid in the US.
Charles BennettApril 4, 2008
Advantages of SenoRx Contura over Mammosite Breast Brachytherapy system.
Analysis of: A new player in the growing Breast Brachytherapy field | www.senorx.com
Author: Charles Bennett, Radiation Oncologist , Robert Boissoneault Oncology Institute
SenoRx has released the Contura system which provides a superior system when compared to the Mammosite Breast Brachytherapy System.  These advantages include: 1.  Better dosimetry, opening the door for more patients to be treated by avoiding the elimination of some patients due to skin spacing...
November 16, 2007
Watch out Tomo....here comes some competition
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: GLG Expert Contributor
Varian and Elekta's new arc treatments improve workflow, efficiency, and give radiation oncologists a better alternative to tomotherapy.    
November 8, 2007
Varian's New Rapid Arc VMAT(Volumetric Modulated Arc Therapy) Technology
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: Lawrence Tena, Radiation Oncologist, St. Vincent's Comprehensive Cancer Center
VMAT is the answer to Tomotherapy and more. This new VMAT technology improves on current IMRT and Tomotherapy.
November 5, 2007
ASTRO 2007: Rapid Arc Efficient, Expensive or both?
Analysis of: Varian's New Rapid Arc Delivery | www.varian.com
Author: GLG Expert Contributor
This article reports on Varian's answer to Tomotherapy which has been gaining some market share in the Radiation Oncology linear accelerator arena. Tomotherapy has a good product but requires a shift in treatment planning technique and complete replacement of hardware. There have been reports about...
October 26, 2007
Let's all exhale
Analysis of: Pfizer Abandons Exubera, Posts 77% Earnings Decline | online.wsj.com
Author: GLG Expert Contributor
This is a big hit for Pfizer - a costly product they licensed due to lack of good pipeline products.   Unfortunatley, I don't think they anticipated the issues surrounding the complexity of inhaled insulin, properly marketed the product, or did enough research on the patient side (ie compliane,...
October 26, 2007
Cardiovascular risks no laughing matter
Analysis of: More Prominence Urged for Heart Risks in Breast Cancer Treatment | www.medpagetoday.com
Author: GLG Expert Contributor
Cardiovascular disease in breast cancer is a real risk.   As our population is aging, and breast cancer is one of the most comon cancers, it is up to us to minimize risks of treatment related morbidity.
October 26, 2007
Pharmaceutical greed and the fleecing of medicare
Analysis of: Genentech to Limit Avastin Availability | online.wsj.com
Author: GLG Expert Contributor
While the data between avastin and lucentis is pending, it's interesting to see Genetch trying to defending profits at the expense of patients.   Genetech has impeded this trial, so that they could defend sales of Lucentis. Before lucentis was approved, avastin was used for macular degeneration...
October 25, 2007
Initial Avastin data interesting
Analysis of: Avastin seen as helpful against deadly brain tumor | www.reuters.com
Author: GLG Expert Contributor
Glioblastoma multiforme are one of the worst tumors one can have - period.   Even with aggressive surgery, chemotherapy and radiation, most of these patients succumb to their disease within 1 year.   Initial results of Avastin + Irinotecan look promising as a second line regimen.  ...

Page : 1 2 3 4 5 6 7 Next1 to 10 of 66

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T21:45:56.203